IBDEI0QL ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13120,2)
 ;;=^295291
 ;;^UTILITY(U,$J,358.3,13121,0)
 ;;=V11.3^^87^830^36
 ;;^UTILITY(U,$J,358.3,13121,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13121,1,4,0)
 ;;=4^V11.3
 ;;^UTILITY(U,$J,358.3,13121,1,5,0)
 ;;=5^Personal h/o Alcoholism
 ;;^UTILITY(U,$J,358.3,13121,2)
 ;;=^295252
 ;;^UTILITY(U,$J,358.3,13122,0)
 ;;=V15.07^^87^830^37
 ;;^UTILITY(U,$J,358.3,13122,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13122,1,4,0)
 ;;=4^V15.07
 ;;^UTILITY(U,$J,358.3,13122,1,5,0)
 ;;=5^Personal h/o Allerlgy to Latex
 ;;^UTILITY(U,$J,358.3,13122,2)
 ;;=^322043
 ;;^UTILITY(U,$J,358.3,13123,0)
 ;;=V13.4^^87^830^38
 ;;^UTILITY(U,$J,358.3,13123,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13123,1,4,0)
 ;;=4^V13.4
 ;;^UTILITY(U,$J,358.3,13123,1,5,0)
 ;;=5^Personal h/o Arthritis
 ;;^UTILITY(U,$J,358.3,13123,2)
 ;;=^295267
 ;;^UTILITY(U,$J,358.3,13124,0)
 ;;=V12.59^^87^830^43
 ;;^UTILITY(U,$J,358.3,13124,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13124,1,4,0)
 ;;=4^V12.59
 ;;^UTILITY(U,$J,358.3,13124,1,5,0)
 ;;=5^Personal h/o Congestive Heart Failure
 ;;^UTILITY(U,$J,358.3,13124,2)
 ;;=^303399
 ;;^UTILITY(U,$J,358.3,13125,0)
 ;;=V45.81^^87^830^44
 ;;^UTILITY(U,$J,358.3,13125,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13125,1,4,0)
 ;;=4^V45.81
 ;;^UTILITY(U,$J,358.3,13125,1,5,0)
 ;;=5^Personal h/o Coronary Bypass
 ;;^UTILITY(U,$J,358.3,13125,2)
 ;;=^97129
 ;;^UTILITY(U,$J,358.3,13126,0)
 ;;=V15.84^^87^830^48
 ;;^UTILITY(U,$J,358.3,13126,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13126,1,4,0)
 ;;=4^V15.84
 ;;^UTILITY(U,$J,358.3,13126,1,5,0)
 ;;=5^Personal h/o Exposure To Asbestos
 ;;^UTILITY(U,$J,358.3,13126,2)
 ;;=^303406
 ;;^UTILITY(U,$J,358.3,13127,0)
 ;;=V15.85^^87^830^68
 ;;^UTILITY(U,$J,358.3,13127,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13127,1,4,0)
 ;;=4^V15.85
 ;;^UTILITY(U,$J,358.3,13127,1,5,0)
 ;;=5^Personal h/o Potentially Hazardous Body Fluids
 ;;^UTILITY(U,$J,358.3,13127,2)
 ;;=^303407
 ;;^UTILITY(U,$J,358.3,13128,0)
 ;;=V10.72^^87^830^52
 ;;^UTILITY(U,$J,358.3,13128,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13128,1,4,0)
 ;;=4^V10.72
 ;;^UTILITY(U,$J,358.3,13128,1,5,0)
 ;;=5^Personal h/o Hodgkin's Disease
 ;;^UTILITY(U,$J,358.3,13128,2)
 ;;=^295237
 ;;^UTILITY(U,$J,358.3,13129,0)
 ;;=V15.3^^87^830^53
 ;;^UTILITY(U,$J,358.3,13129,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13129,1,4,0)
 ;;=4^V15.3
 ;;^UTILITY(U,$J,358.3,13129,1,5,0)
 ;;=5^Personal h/o Irradiation
 ;;^UTILITY(U,$J,358.3,13129,2)
 ;;=^295285
 ;;^UTILITY(U,$J,358.3,13130,0)
 ;;=V10.82^^87^830^60
 ;;^UTILITY(U,$J,358.3,13130,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13130,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,13130,1,5,0)
 ;;=5^Personal h/o Mal Melanoma of Skin
 ;;^UTILITY(U,$J,358.3,13130,2)
 ;;=Hx of Malignant Melanoma^295240
 ;;^UTILITY(U,$J,358.3,13131,0)
 ;;=V15.81^^87^830^34
 ;;^UTILITY(U,$J,358.3,13131,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13131,1,4,0)
 ;;=4^V15.81
 ;;^UTILITY(U,$J,358.3,13131,1,5,0)
 ;;=5^Noncompliance With Medical Treatment
 ;;^UTILITY(U,$J,358.3,13131,2)
 ;;=^295290
 ;;^UTILITY(U,$J,358.3,13132,0)
 ;;=V10.43^^87^830^66
 ;;^UTILITY(U,$J,358.3,13132,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13132,1,4,0)
 ;;=4^V10.43
 ;;^UTILITY(U,$J,358.3,13132,1,5,0)
 ;;=5^Personal h/o Ovarian Cancer
 ;;^UTILITY(U,$J,358.3,13132,2)
 ;;=Hx of Ovarian CA^295221
 ;;^UTILITY(U,$J,358.3,13133,0)
 ;;=V10.46^^87^830^69
 ;;^UTILITY(U,$J,358.3,13133,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13133,1,4,0)
 ;;=4^V10.46
 ;;^UTILITY(U,$J,358.3,13133,1,5,0)
 ;;=5^Personal h/o Prostate Cancer
